The Observation Of A Case Of Advanced Primary Retroperitoneal Leiomyosarcoma Treated With Apatinib And Literature Review

Objective: The safety and efficacy of apatinib in treatment of advanced primary retroperitoneal leiomyosarcoma.Methods: the clinical efficacy and safety were observed in a case of patient with advanced primary retroperitoneal leiomyosarcoma,who oral apatinib treatment after multiline chemotherapy is ineffective.Results: The patient's abdominal distention and pain relief.At the end of April 24,2018,the progression free survival time was 6.5 months.The best effect was stable disease.The main side effects were grade 3 hypertension(control)and grade 2 hand foot syndrome.Conclusion: The case of primary retroperitoneal leiomyosarcoma patient using apatinib monotherapy showed better efficacy.apatinib has less adverse reactions,it may become the drug of targeted therapy in selected patients who with advanced primary retroperitoneal leiomyosarcoma.